BioLineRx Ltd. (BLRX) stock
BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.12−0.03 (-2.61%)
Close on Nov 17, 2026Market cap $4.87MP/E –Yield –
BioLineRx r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $8.09M, down 11.5% from the year before. Over ten years it grew -3.4% a year on average. The highest annual figure on record is $23.44M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.09M | -11.5% |
| FY2024 | Dec 31, 2024 | $9.15M | -26.9% |
| FY2023 | Dec 31, 2023 | $12.52M | -29.0% |
| FY2022 | Dec 31, 2022 | $17.63M | -9.4% |
| FY2021 | Dec 31, 2021 | $19.47M | +7.1% |
| FY2020 | Dec 31, 2020 | $18.17M | -22.5% |
| FY2019 | Dec 31, 2019 | $23.44M | +18.3% |
| FY2018 | Dec 31, 2018 | $19.81M | +1.5% |
| FY2017 | Dec 31, 2017 | $19.51M | +74.6% |
| FY2016 | Dec 31, 2016 | $11.18M | -2.7% |
| FY2015 | Dec 31, 2015 | $11.49M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.94M | -45.4% |
| Q2 FY2025 | Jun 30, 2025 | $2.33M | -54.7% |
| Q2 FY2024 | Jun 30, 2024 | $2.23M | -52.0% |
| Q2 FY2023 | Jun 30, 2023 | $3.01M | -43.3% |
| Q2 FY2022 | Jun 30, 2022 | $5.40M | +20.3% |
| Q2 FY2021 | Jun 30, 2021 | $5.14M | +26.5% |
| Q2 FY2020 | Jun 30, 2020 | $4.64M | – |
| Q2 FY2019 | Jun 30, 2019 | $5.30M | – |
| Q2 FY2018 | Jun 30, 2018 | $4.48M | – |
| Q2 FY2017 | Jun 30, 2017 | $4.06M | – |
See a number that looks wrong?